No, women should not breastfeed while taking tamoxifen.
Tamoxifen is explicitly contraindicated in nursing mothers, and breastfeeding must be discontinued during treatment 1, 2. This is a clear, unequivocal recommendation from both ASCO clinical practice guidelines and FDA drug labeling.
Evidence Supporting This Recommendation
Guideline-Based Contraindication
The ASCO clinical practice guidelines (2013,2019) consistently state that tamoxifen is not recommended for women who are nursing mothers 1, 2. This recommendation applies to:
- Women using tamoxifen for breast cancer risk reduction
- Women with DCIS
- Women receiving adjuvant treatment for breast cancer
FDA Drug Label Warning
The FDA label explicitly states: "Because of the potential for serious adverse reactions in nursing infants from tamoxifen, women taking tamoxifen should not breast feed" 3. This warning appears multiple times throughout the official prescribing information.
Pharmacokinetic Evidence
First-in-human data (2020) definitively demonstrates that tamoxifen and its active metabolites transfer into breast milk 4. Key findings:
- Tamoxifen concentrations in milk reached 214 nM
- Active metabolites (Z-4-hydroxy-tamoxifen and Z-endoxifen) reached clinically significant levels after 18 days
- Tamoxifen has complete oral bioavailability, meaning an infant would absorb the drug if breastfed
- The drug has a long half-life (>7 days), leading to accumulation
Mechanism of Harm
Tamoxifen poses multiple risks to nursing infants:
Direct toxicity: Animal studies show that neonatal exposure causes reproductive tract lesions in female rodents (similar to DES exposure in humans) and functional defects in male rodents including testicular atrophy and arrested spermatogenesis 3
Lactation suppression: Tamoxifen inhibits milk production itself, making sustained breastfeeding difficult 3, 5
Unknown long-term effects: The impact on infant development is not fully characterized, but given tamoxifen's anti-estrogenic effects during a critical developmental period, the potential for harm is substantial
Clinical Implementation
If a woman is taking tamoxifen:
- She must use formula feeding exclusively
- She should not attempt to breastfeed at all
- If pregnancy occurs during treatment, tamoxifen should be stopped immediately and breastfeeding avoided
If a woman desires to breastfeed:
- Tamoxifen must be discontinued
- Given the 7+ day half-life and demonstrated accumulation in milk over weeks, a washout period would be necessary before breastfeeding could be considered safe
- Alternative feeding methods must be used during tamoxifen therapy
Critical Caveat
The 2020 pharmacokinetic study 4 provides the first human evidence of tamoxifen transfer into milk, confirming what was previously theoretical concern based on animal data. This strengthens the existing guideline recommendations and eliminates any ambiguity about whether the drug actually enters breast milk.